Aachen, Germany, December 2nd 2013. The Grünenthal Group today announced that the supervisory board of the international pharmaceutical company prolonged the contract with the chairman of its Corporate Executive Board, Professor Dr. Eric-Paul Pâques, ahead of time and confirmed him in office as Chief Executive Officer for another three years. Professor Pâques had taken over the leadership of the pain specialist with its international headquarters in Aachen in May this year.
“In a highly regulated industry that is facing price pressures, the challenges to remain an independent, family-owned business will increase. The supervisory board and the family shareholders of Grünenthal Group are convinced that as Chief Executive Officer and with his knowledge about the company and extensive experience in the pharmaceutical sector, Professor Pâques will be leading Grünenthal into a successful future”, commented Dr. Wilhelm Moll, Chairman of the Supervisory Board of Grünenthal Group, on this key decision.
In his function as Chief Executive Officer, Professor Pâques will continue to focus on accelerating internal and external growth and explore new business opportunities. Next to activities on the enlargement of its product portfolio, Grünenthal has recently launched a public tender offer for all outstanding shares of a pharmaceutical company in Latin America.
The Grünenthal Group is an independent, family-owned, international research-based pharmaceutical company headquartered in Aachen, Germany. Building on its unique position in pain treatment, its objective is to become the most patient-centric company and thus to be a leader in therapy innovation.
Grünenthal is one of the last five remaining research-oriented pharmaceutical companies with headquarters in Germany which sustainably invests in research and development. Research and development costs amounted to about 26 percent of revenues in 2012. Grünenthal’s research and development strategy concentrates on selected fields of therapy and state-of-the-art technologies. We are intensely focused on discovering new ways to treat pain better and more effectively, with fewer side-effects than current therapies.
Altogether, the Grünenthal Group has affiliates in 26 countries worldwide. Grünenthal products are sold in more than 155 countries. Today, approx. 4,400 employees are working for the Grünenthal Group worldwide. In 2012, Grünenthal achieved revenues of €973 mn.
More information: www.grunenthal.com.